ProQR Therapeutics NV

ProQR Therapeutics NV

ProQR Therapeutics NV

Date Founded



Zernikedreef 9,Leiden, Zuid-Holland 2333 CK

Type of Company


Employees (Worldwide)




Company Description

ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Contact Data
Trying to get in touch with decision makers at ProQR Therapeutics NV? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees



Chief Financial & Business Officer

Chief Scientific Officer

Vice President, Head of Commercial

Vice President, Business Development

Vice President Medical Affairs

Vice President of Investor Relations & Corporate Communications

Vice President, Human Resources

Supervisory Board

Managing Director at Stichting Administratiekantoor Endavit

General Manager-Sanofi BioSurgery Business Unit at Genzyme Corp.

Chairman at Sofinnova Partners SAS

Former Chief Medical Officer at GlaxoSmithKline Plc

Chief Executive Officer at Freeline Therapeutics Ltd.

Chief Operating Officer & Chief Financial Officer at Galapagos NV

Paths to ProQR Therapeutics NV
Potential Connections via
Relationship Science
ProQR Therapeutics NV
Owners & Shareholders
Details Hidden

Aquilo Capital Management focuses on long/short investments in the stocks of companies in the life sciences and biotechnology sectors

Details Hidden

DAFNA evaluates investments by identifying significant events that will likely affect a company’s stock price upwards or downwards. The firm monitors the progress and suitability of portfolio investments as well as market and economic outlook. Their sources of information they may use include commercially available information services and financial publications dealing with investment research, securities law and taxation. Such information may be obtainable in print, via the internet or by some other means. Issuer-prepared materials (particularly prospectuses), private placement due diligence materials, and research releases prepared by third parties are also utilized. DAFNA may also use research materials prepared by various investment product vendors or custodians as well as in-house analysts.

Details Hidden

De Grote Voskuil Capital aims to achieve long-term capital growth at an acceptable risk. The Hoofbosch Beleggingsfonds invests the majority of its assets (currently around 75%) in solid listed companies in sectors such as consumer goods, pharmaceuticals and energy. They don’t invest the fund in derivatives, real estate, emerging markets, technology or financial services. About 10% of the fund is currently invested in 'specials' or opportunities outside the fund's philosophy. The fund can also invest up to 5% in gold and up to 10% is invested in government bonds of Switzerland and the Netherlands.

Recent Transactions
Details Hidden

ProQR Therapeutics NV issued . USD Ordinary Shares

Details Hidden

ProQR Therapeutics NV issued USD Common Stock

Details Hidden

ProQR Therapeutics NV issued . USD Ordinary Shares

Transaction Advisors
Escrow Agent

Advised onProQR Therapeutics NV issued USD Common Stock


Advised onProQR Therapeutics NV issued USD Common Stock


Advised onProQR Therapeutics NV issued USD Common Stock


Advised onProQR Therapeutics NV issued USD Ordinary Shares

Managing Director

Advised onProQR Therapeutics NV issued USD Common Stock

Legal Advisor

Advised onProQR Therapeutics NV issued USD Ordinary Shares

Advisors & Consultants
Special Advisor

Chief Medical Officer at Kezar Life Sciences, Inc.

Legal Advisor

Attorney at Goodwin Procter LLP


Former Chief Scientific Officer at ProQR Therapeutics NV

Key Stats and Financials As of 2019
Market Capitalization
Total Enterprise Value
Earnings Per Share
Net Profit
TEVNet Income
Debt TEV
Total Equity
Total Debt
Details Hidden

Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands.

Details Hidden

Gilde Healthcare Partners BV operates as a venture capital firm that specializes in management buy-outs and growth capital investments in start-up, seed, growth stage, emerging growth, lower middle market, expansion, early, mid, and late stage companies in the healthcare technology and healthcare services sector. It focuses on Healthcare providers and suppliers of goods and services to healthcare providers, biopharma, pharmaceutical, clinical stage therapeutics companies, diagnostics, medical devices, healthcare services including home healthcare services, medical technology, digital healthcare, life sciences, and supporting technologies. The company was founded by Pieter van der Meer and Edwin W. de Graaf in 1999 and is headquartered in Utrecht, the Netherlands

Details Hidden

Sofinnova Partners is an active manager which invests exclusively in life sciences and information technology firms in France, Europe, and to a limited extent, the US. They also have expertise in the clean technology sector. The firm aims to build companies from seed rounds to a trade sale or an IPO, investing in start-ups and early-stage companies with ambitious projects. They a minimum of 0.5 million euros per investment, and up to 20 million euros over several rounds of financing.Sofinnova acts as lead or co-lead investor, taking a seat on the board of directors and seeking to bring added value to the investee company management team.

Details Hidden

President at Mossrock Capital LLC

Government of France Holding Companies | Paris, France

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by ProQR Therapeutics NV. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of ProQR Therapeutics NV's profile does not indicate a business or promotional relationship of any kind between RelSci and ProQR Therapeutics NV.